2023年6月24日，勃林格殷格翰和Zealand Pharma公布试验数据表明，在接受46周治疗、不伴有2型糖尿病的超重或肥胖受试者中，Survodutide（又称为BI 456906）的疗效优于安慰剂[1]。上述发现已在美国加利福尼亚州圣地亚哥举行的2023年美国糖尿病协会第83届大会上公布。II期研究包括两项分析：计划治疗分析（随机分组时...
勃林格殷格翰和Zealand Pharma(纳斯达克股票代码:ZEAL)6月24日公布试验数据表明,在接受46周治疗、不伴有2型糖尿病的超重或肥胖受试者中,Survodutide(又称为BI 456906)的疗效优于安慰剂。1上述发现已在美国加利福尼亚州圣地亚哥举行...
1. le Roux CW et al. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People with Overweight/Obesity. Presented at the American Diabetes Association’s 83rd Scientific Sessions 2023; 23 June 2023. 51-OR. 2. T. Zimmerman et al. BI 456906: Dis...
勃林格殷格翰和Zealand Pharma(纳斯达克股票代码:ZEAL)6月24日公布试验数据表明,在接受46周治疗、不伴有2型糖尿病的超重或肥胖受试者中,Survodutide(又称为BI 456906)的疗效优于安慰剂。1 上述发现已在美国加利福尼亚州圣地亚哥举行的2023年美国糖尿病协会第83届大会上公布。 II期研究包括两项分析:计划治疗分析(...
这是一项由295名参与者参加的II期随机双盲安慰剂对照剂量摸底试验(NCT04771273),旨在评估每周皮下注射Survodutide(BI 456906)对患有或未患有2型糖尿病的成人MASH和纤维化(F1-F3)患者的治疗效果。 试验的主要终点是经过 48 周治疗后,MASH 组织学改善而纤维化不恶化的参与者比例。MASH 组织学改善的定义是非酒精性...
“With our long heritage in researching and developing new treatments for cardiovascular, renal, and metabolic conditions, we are extremely encouraged by these robust and compelling Phase II data,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. “Survodutide may become the firs...
“We believe that BI 456906 has great therapeutic potential, and we are thrilled to see it advance into Phase 2 development,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Our strong partnership with Boehringer Ingelheim unites expertise and capabilities to achieve...
Phase I Study of glucagon-like peptide-1/glucagon receptor dual agonist BI 456906 in obesity (Poster 231) Obesity, 29 (S2) (2021), pp. 139-140 Google Scholar [48] M.L. Boland, R.C. Laker, K. Mather, A. Nawrocki, S. Oldham, B.B. Boland, et al. Resolution of NASH and hepati...
OS-119 Survodutide (BI 456906), a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in people with compensated and decompensated cirrhosis: a multinational, open-label, phase 1 trial 来自 dx.doi.org 喜欢 0 阅读量: 7 ...
德国殷格翰和丹麦哥本哈根,2023年6月23日-勃林格殷格翰和Zealand Pharma(纳斯达克股票代码:ZEAL)公布试验数据表明,在接受46周治疗、不伴有2型糖尿病的超重或肥胖受试者中,Survodutide(又称为BI 456906)的疗效优于安慰剂。¹ 上述...